Asprega ProPac Launched for AAD

Share this article:

Scimera BioScience announced the launch of Asprega ProPac (saccharomyces boulardii 20 billion CFUs) delayed-release capsules, a probiotic to relieve gastrointestinal side effects of antibiotic therapy including antibiotic-associated diarrhea (AAD).

ProPac uses the same blend of 11 probiotic strains and saccharomyces boulardii yeast found in Scimera's Asprega product. Asprega ProPac contains 20 billion colony forming units (CFUs), and its delayed-release capsule formulation delivers efficacy deeper in the digestive tract.

Asprega ProPac is packaged in a 10-day course to be taken along with a typical 10-day course of antibiotics.

For more information call (855) 724-6372 or visit www.scimera.com
Share this article:

Related Resources